Nesvåg Ragnar, Hartz Ingeborg, Bramness Jørgen G, Hjellvik Vidar, Handal Marte, Skurtveit Svetlana
Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
Faculty of Public Health, Hedmark University of Applied Sciences, Elverum, Norway; Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway.
Eur Neuropsychopharmacol. 2016 Sep;26(9):1412-1418. doi: 10.1016/j.euroneuro.2016.07.001. Epub 2016 Jul 21.
Antipsychotic drugs are used increasingly by children and adolescents and there is concern about off-label use. We aimed to study which substances, and for which mental disorder diagnoses, antipsychotic drugs were prescribed to 0-18-year-old boys and girls in Norway. Linked data from the national health registry for prescription drugs in 2010 and mental disorder diagnoses in 2008-2012 were used to study the prevalence of antipsychotic drug use, the type of antipsychotic drug substances used, mental disorder diagnoses in users and distribution of drugs per diagnostic category across gender. In total, 0.18% of Norwegian children and adolescents were prescribed antipsychotic drugs during 2010, of which there were more boys (0.23%) than girls (0.13%). Risperidone was the most frequently used substance among boys (57.4%) and girls (32.3%), followed by aripiprazole (19.4%) in boys and quetiapine (27.4%) in girls. The most common mental disorder diagnoses among male users were hyperkinetic (49.9%) and autism spectrum disorder (27.1%), while anxiety disorders (41.5%) and depressive illness (33.6%) were most common among female users. A schizophrenia-like psychosis diagnosis was given to 11.1% of the male and 18.2% of the female users. A hyperkinetic disorder was diagnosed among 56.9% and 52.4% of the male risperidone and aripiprazole users, respectively. Among female quetiapine users, 57.1% were diagnosed with anxiety disorders and 52.4% with depressive illness. These results demonstrate that children and adolescents who use antipsychotic drugs are predominantly diagnosed with non-psychotic mental disorders such as hyperkinetic disorder among boys and anxiety disorder or depressive illness among girls.
抗精神病药物在儿童和青少年中的使用越来越多,人们对其超适应症使用情况表示担忧。我们旨在研究挪威0至18岁男孩和女孩被开具抗精神病药物用于哪些物质以及哪些精神障碍诊断。利用2010年国家药品健康登记处的关联数据以及2008 - 2012年的精神障碍诊断数据,研究抗精神病药物的使用 prevalence、使用的抗精神病药物物质类型、使用者的精神障碍诊断以及各诊断类别药物在不同性别中的分布情况。2010年,共有0.18%的挪威儿童和青少年被开具抗精神病药物,其中男孩(0.23%)多于女孩(0.13%)。利培酮是男孩(57.4%)和女孩(32.3%)中最常使用的物质,其次是男孩中的阿立哌唑(19.4%)和女孩中的喹硫平(27.4%)。男性使用者中最常见的精神障碍诊断是多动障碍(49.9%)和自闭症谱系障碍(27.1%),而女性使用者中焦虑症(41.5%)和抑郁症(33.6%)最为常见。11.1%的男性使用者和18.2%的女性使用者被诊断为精神分裂症样精神病。在使用利培酮的男性中,56.9%被诊断为多动障碍,在使用阿立哌唑的男性中,这一比例为52.4%。在使用喹硫平的女性中,57.1%被诊断为焦虑症,52.4%被诊断为抑郁症。这些结果表明,使用抗精神病药物的儿童和青少年主要被诊断为非精神病性精神障碍,如男孩中的多动障碍以及女孩中的焦虑症或抑郁症。